5 Best Performing NASDAQ Stocks According to Wall Street Analysts

2. Opus Genetics Inc. (NASDAQ:IRD)

6-Month Performance: 165.48%

Average Upside Potential: 83.05%

Opus Genetics Inc. (NASDAQ:IRD) is one of the best performing NASDAQ stocks according to Wall Street analysts. On April 6, Opus Genetics secured a financing agreement with Oberland Capital, providing up to $155 million in non-dilutive funding and a $5 million equity investment. This capital infusion, combined with current resources, extends the company’s cash runway into 2029. The funding is designated to support the completion of pivotal studies for OPGx-LCA5 and OPGx-BEST1, initiate pre-launch commercial activities, and advance earlier-stage pipeline programs into clinical testing.

The agreement includes an upfront payment of $35 million in notes and a concurrent purchase of 1.1 million shares of common stock at $4.48 per share. Opus Genetics can access additional tranches of funding over the next 2 years based on clinical milestones, including the potential regulatory approval of its LCA5 program. The notes carry a 7-year maturity with a 6-year interest-only period, providing the financial flexibility to leverage the company’s gene therapy platform while maintaining a focus on inherited retinal diseases/IRDs.

With a strengthened balance sheet, Opus Genetics Inc. (NASDAQ:IRD) plans to transition three additional programs into the clinic over the next year: OPGx-RDH12, OPGx-MERTK, and OPGx-RHO. These programs target rare conditions that cause blindness and affect tens of thousands of patients globally. The company remains on track to report topline results from its Phase 1/2 trial of OPGx-BEST1 in mid-2026, marking a critical step toward restoring vision for patients with limited treatment options.

Opus Genetics Inc. (NASDAQ:IRD) is involved in the research and development of ophthalmic biopharmaceutical products, with a focus on the development and commercialization of therapies for the treatment of several eye disorders.